IL295394A - Preparation of a p2x3 antagonist - Google Patents
Preparation of a p2x3 antagonistInfo
- Publication number
- IL295394A IL295394A IL295394A IL29539422A IL295394A IL 295394 A IL295394 A IL 295394A IL 295394 A IL295394 A IL 295394A IL 29539422 A IL29539422 A IL 29539422A IL 295394 A IL295394 A IL 295394A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- reaction
- contacting
- produce
- followed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977004P | 2020-02-14 | 2020-02-14 | |
| US202163144902P | 2021-02-02 | 2021-02-02 | |
| PCT/IB2021/000130 WO2021161109A1 (en) | 2020-02-14 | 2021-02-12 | Preparation of a p2x3 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295394A true IL295394A (en) | 2022-10-01 |
Family
ID=77292130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295394A IL295394A (en) | 2020-02-14 | 2021-02-12 | Preparation of a p2x3 antagonist |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12503470B2 (https=) |
| EP (1) | EP4103572A4 (https=) |
| JP (1) | JP7693691B2 (https=) |
| KR (1) | KR20220140804A (https=) |
| CN (1) | CN115427419B (https=) |
| AU (1) | AU2021219992A1 (https=) |
| BR (1) | BR112022015818A2 (https=) |
| CA (1) | CA3184277A1 (https=) |
| IL (1) | IL295394A (https=) |
| MX (1) | MX2022009765A (https=) |
| WO (1) | WO2021161109A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7578602B2 (ja) | 2019-02-25 | 2024-11-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | Ｐ２ｘ３修飾薬での治療 |
| WO2022156783A1 (zh) * | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物的制备方法及其中间体 |
| CN114805237B (zh) * | 2021-01-22 | 2026-04-21 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
| WO2022161462A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| WO2023021328A1 (en) * | 2021-08-17 | 2023-02-23 | Bellus Health Cough Inc. | Preparation of a p2x3 antagonist |
| EP4577528A1 (en) * | 2022-08-25 | 2025-07-02 | 14245563 Canada Inc. | Preparation of a p2x3 antagonist |
| WO2025125445A1 (en) | 2023-12-12 | 2025-06-19 | Glaxosmithkline Intellectual Property (No.3) Limited | Process of manufacture of p2x3 antagonists including camlipixant |
| WO2025191081A1 (en) | 2024-03-15 | 2025-09-18 | Glaxosmithkline Intellectual Property (No.3) Limited | Crystalline form of camlipixant |
| WO2026022326A1 (en) | 2024-07-25 | 2026-01-29 | Glaxosmithkline Intellectual Property (No.3) Limited | P2x3 antagonist formulation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010229142A1 (en) * | 2009-03-23 | 2011-10-13 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| CN102358739B (zh) * | 2011-04-29 | 2013-02-20 | 中国科学院广州生物医药与健康研究院 | 咪唑[1,2-a]吡啶和咪唑醛类化合物的合成方法 |
| DK3381917T3 (da) * | 2013-01-31 | 2021-10-18 | Bellus Health Cough Inc | Imidazopyridinforbindelser og anvendelser deraf |
| US10111883B1 (en) | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| KR102797127B1 (ko) * | 2018-12-29 | 2025-04-21 | 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 | 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도 |
| EP4103564A4 (en) * | 2020-02-14 | 2024-05-01 | GlaxoSmithKline Intellectual Property (No.3) Limited | P2X3 MODULATORS |
| WO2021244634A1 (zh) | 2020-06-05 | 2021-12-09 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| EP4169921A4 (en) | 2020-06-29 | 2024-06-19 | Wuhan LL Science and Technology Development Co., Ltd. | Crystalline form of heterocyclic compound, preparation method therefor and application thereof |
| WO2022156783A1 (zh) | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物的制备方法及其中间体 |
| CN114805237B (zh) | 2021-01-22 | 2026-04-21 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
-
2021
- 2021-02-12 CN CN202180028877.XA patent/CN115427419B/zh active Active
- 2021-02-12 JP JP2022548876A patent/JP7693691B2/ja active Active
- 2021-02-12 EP EP21754068.1A patent/EP4103572A4/en active Pending
- 2021-02-12 WO PCT/IB2021/000130 patent/WO2021161109A1/en not_active Ceased
- 2021-02-12 US US17/929,027 patent/US12503470B2/en active Active
- 2021-02-12 AU AU2021219992A patent/AU2021219992A1/en not_active Abandoned
- 2021-02-12 IL IL295394A patent/IL295394A/en unknown
- 2021-02-12 BR BR112022015818A patent/BR112022015818A2/pt unknown
- 2021-02-12 CA CA3184277A patent/CA3184277A1/en active Pending
- 2021-02-12 MX MX2022009765A patent/MX2022009765A/es unknown
- 2021-02-12 KR KR1020227031508A patent/KR20220140804A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7693691B2 (ja) | 2025-06-17 |
| BR112022015818A2 (pt) | 2022-10-25 |
| MX2022009765A (es) | 2022-09-09 |
| US20230101612A1 (en) | 2023-03-30 |
| JP2023513738A (ja) | 2023-04-03 |
| KR20220140804A (ko) | 2022-10-18 |
| CA3184277A1 (en) | 2021-08-19 |
| CN115427419A (zh) | 2022-12-02 |
| EP4103572A4 (en) | 2024-03-06 |
| WO2021161109A1 (en) | 2021-08-19 |
| CN115427419B (zh) | 2026-04-21 |
| EP4103572A1 (en) | 2022-12-21 |
| US12503470B2 (en) | 2025-12-23 |
| AU2021219992A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295394A (en) | Preparation of a p2x3 antagonist | |
| IL294225A (en) | Method of preparation of a protein-degrading agent compound and application | |
| NZ539390A (en) | Azaindole derivatives as inhibitors of p38 kinase | |
| US11352316B2 (en) | Opioid receptor modulators and products and methods related thereto | |
| IL273243B2 (en) | A compound with a cyclic structure | |
| EP1532124B1 (en) | Use of nitrile derivatives as medicament. | |
| JP2023541944A (ja) | Ｍａｓ関連ｇタンパク質受容体ｘ４のモジュレーター、並びに関連製品及び方法 | |
| IL302651A (en) | Integrin inhibitors and their uses | |
| IL225808A (en) | Sesquihydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate, process for its preparation and pharmaceutical compositions comprising it for treating diabetes and obesity | |
| IL295393A (en) | P2x3 modulators | |
| JP2025501086A (ja) | 痛風または高尿酸血症の処置のための化合物の調製 | |
| WO2023021328A1 (en) | Preparation of a p2x3 antagonist | |
| IL259297B (en) | Heterocyclic compounds for the treatment of disease | |
| IL296532A (en) | Crystal forms of farnesoid x receptor agonist | |
| US9567347B2 (en) | Use of small molecule inhibitors targeting the interaction between RAC GTPase and p67(phox) | |
| IL280243B1 (en) | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure | |
| JP2026504060A (ja) | Ｓ１ｐ受容体モジュレーターの調製 | |
| IL315993A (en) | Tetrahydronaphthalene derivative | |
| JP2004532854A (ja) | 複素２環式ｆｋｂｐリガンド | |
| JP2025527691A (ja) | Ｐ２ｘ３アンタゴニストの製造 | |
| HK40084747A (en) | Preparation of a p2x3 antagonist | |
| EP4720063A1 (en) | Naphthyridinone derivatives for the treatment of a disease or disorder | |
| HK40113882A (zh) | 用於治疗痛风或高尿酸血症的化合物的制备 | |
| IL302014A (en) | Transformed aromatic compounds and their pharmaceutical preparations |